2016
Emerging biomarkers for PD-1 pathway cancer therapy
Lim J, Sundar R, Chnard-Poirier M, Lopez J, Yap T. Emerging biomarkers for PD-1 pathway cancer therapy. Biomarkers In Medicine 2016, 11: 53-67. PMID: 27936870, DOI: 10.2217/bmm-2016-0228.Peer-Reviewed Original ResearchConceptsPD-L1Predictive biomarkers of responseImmune checkpoint inhibitorsImmune-related toxicitiesPD-L1 expressionPD-L1 inhibitorsBiomarkers of responseTreatment response biomarkersMultiple tumor typesIntermediate end pointsCheckpoint inhibitorsPD-1Predictive biomarkersImmuno-oncologyResponse assessmentTumor typesResponse biomarkersCancer therapyEnd pointsTherapy designBiomarkersFDA registrationTreatmentInhibitorsDifferential responding
2014
Immunotherapy in the treatment of non-small cell lung cancer
Sundar R, Soong R, Cho B, Brahmer J, Soo R. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014, 85: 101-109. PMID: 24880938, PMCID: PMC4332778, DOI: 10.1016/j.lungcan.2014.05.005.Peer-Reviewed Original ResearchConceptsImmune response to tumorsTreatment of non-small cell lung cancerNon-small cell lung cancerProlonged clinical responsesImmune checkpoint modulatorsImmune checkpoint pathwaysPD-L1 inhibitorsResponse to tumorsCell lung cancerCTLA-4PD-1PD-L1Tolerable toxicityTumor immunosurveillanceCheckpoint modulatorsCo-stimulatoryCo-inhibitoryClinical responseImmunotherapeutic agentsPredictive biomarkersImmune destructionLung cancerTreatment selectionImmune systemInhibitory molecules